HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

L’Oréal

This article was originally published in The Rose Sheet

Executive Summary

Jean-Paul Agon is appointed CEO of French beauty giant during annual general meeting April 25 in Paris. Company announced plan for Agon to succeed Lindsay Owen-Jones, who retains his role as chairman, last year (1"The Rose Sheet" Feb. 21, 2005, p. 5). Agon will oversee integration of recently acquired British beauty retailer The Body Shop, which is "well underway," Owen-Jones states during the meeting. Outlining future growth opportunities for the company, Owen-Jones cites consumers over 60 and men as audiences to explore. L'Oréal is in a "strong position" to tap older customers with anti-aging products like Lancôme Platineum and has a number of brands targeted to men, including L'Oréal Paris Men Expert and Biotherm Homme, exec notes, adding sales of its men's products were up 17.8% in 2005...

You may also be interested in...



L’Oréal Taps Agon To Lead Business; Owen-Jones To Remain Chairman

L'Oréal USA President Jean-Paul Agon will succeed Chairman and CEO Lindsay Owen-Jones at the helm of the French beauty company in 2006 under a new management structure in which Owen-Jones will retain his chairmanship

US Bill Urges Automatic Insulin Interchangeability

A draft Biosimilar Insulin Access Act, intended to waive US interchangeability requirements for FDA-approved biosimilar insulins, has been introduced by representative Glenn Grothman.

Ex-Cipla Executive To Helm JB Chemicals

The former CEO of Cipla’s India business is set to steer JB Chemicals and Pharmaceuticals, as the Indian firm embarks on a new phase of growth, backed by a revamped board, following its takeover by US private equity firm KKR.

UsernamePublicRestriction

Register

ID1132028

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel